Lisata Therapeutics (LSTA) Competitors $2.70 +0.07 (+2.66%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.66 -0.04 (-1.48%) As of 07/15/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. MGNX, ORMP, CLLS, JMAC, IVVD, FBRX, EXOZ, CLYM, IGMS, and ENTXShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include MacroGenics (MGNX), Oramed Pharmaceuticals (ORMP), Cellectis (CLLS), Maxpro Capital Acquisition (JMAC), Invivyd (IVVD), Forte Biosciences (FBRX), eXoZymes (EXOZ), Climb Bio (CLYM), IGM Biosciences (IGMS), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors MacroGenics Oramed Pharmaceuticals Cellectis Maxpro Capital Acquisition Invivyd Forte Biosciences eXoZymes Climb Bio IGM Biosciences Entera Bio MacroGenics (NASDAQ:MGNX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Is MGNX or LSTA more profitable? Lisata Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -36.23%. MacroGenics' return on equity of -59.84% beat Lisata Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-36.23% -59.84% -23.45% Lisata Therapeutics N/A -61.37%-53.35% Which has more risk and volatility, MGNX or LSTA? MacroGenics has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Do insiders & institutionals have more ownership in MGNX or LSTA? 96.9% of MacroGenics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 13.0% of MacroGenics shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor MGNX or LSTA? In the previous week, Lisata Therapeutics had 3 more articles in the media than MacroGenics. MarketBeat recorded 6 mentions for Lisata Therapeutics and 3 mentions for MacroGenics. Lisata Therapeutics' average media sentiment score of 1.04 beat MacroGenics' score of 0.64 indicating that Lisata Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lisata Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MGNX or LSTA? MacroGenics currently has a consensus target price of $5.71, indicating a potential upside of 283.51%. Lisata Therapeutics has a consensus target price of $23.50, indicating a potential upside of 770.37%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Lisata Therapeutics is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, MGNX or LSTA? Lisata Therapeutics has lower revenue, but higher earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$149.96M0.63-$66.97M-$0.89-1.67Lisata Therapeutics$1M23.27-$19.99M-$2.30-1.17 SummaryMacroGenics and Lisata Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.66M$2.96B$5.62B$9.29BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-1.1720.2228.5719.58Price / Sales23.27290.24423.3293.40Price / CashN/A43.1536.0257.93Price / Book0.777.568.135.54Net Income-$19.99M-$55.11M$3.24B$257.73M7 Day Performance-7.85%3.81%0.16%-0.08%1 Month Performance7.57%11.60%5.95%8.09%1 Year Performance-27.03%-2.11%26.09%13.02% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.815 of 5 stars$2.70+2.7%$23.50+770.4%-25.6%$22.66M$1M-1.1730News CoveragePositive NewsAnalyst ForecastGap DownHigh Trading VolumeMGNXMacroGenics4.3003 of 5 stars$1.40+2.6%$5.71+309.6%-69.2%$88.01M$152.43M-1.57430ORMPOramed Pharmaceuticals1.0336 of 5 stars$2.14-0.9%N/A-17.4%$87.42M$1.34M-4.8610CLLSCellectis3.2695 of 5 stars$1.58-1.3%$4.00+153.3%+1.0%$87.26M$49.22M-1.83290Positive NewsGap UpJMACMaxpro Capital AcquisitionN/A$6.44+4.9%N/A+2,834.6%$86.48MN/A0.002,021IVVDInvivyd3.4292 of 5 stars$0.71+1.5%$5.85+719.3%-47.1%$85.65M$36.69M-0.59100FBRXForte Biosciences3.499 of 5 stars$12.75+0.8%$61.00+378.4%+42,163.0%$83.90MN/A-0.785Positive NewsEXOZeXoZymesN/A$9.95-2.3%N/AN/A$83.28M$70K0.0029Positive NewsGap DownCLYMClimb Bio3.472 of 5 stars$1.23-2.4%$9.00+631.7%N/A$83.12MN/A-0.529Positive NewsIGMSIGM Biosciences4.6415 of 5 stars$1.37+1.1%$5.50+302.9%-87.0%$81.60M$2.68M-0.42190Positive NewsENTXEntera Bio2.5773 of 5 stars$1.80-1.9%$10.00+457.1%+0.5%$81.58M$180K-6.9020 Related Companies and Tools Related Companies MacroGenics Competitors Oramed Pharmaceuticals Competitors Cellectis Competitors Maxpro Capital Acquisition Competitors Invivyd Competitors Forte Biosciences Competitors eXoZymes Competitors Climb Bio Competitors IGM Biosciences Competitors Entera Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LSTA Stock Alerts